A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults
<p>We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3 study, severe acute respiratory syndrome...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2024
|
| _version_ | 1811140159710691328 |
|---|---|
| author | Iwata, S Pollard, AJ Tada, Y Omoto, S Shibata, RY Igarashi, K Hasegawa, T Ariyasu, M Sonoyama, T |
| author_facet | Iwata, S Pollard, AJ Tada, Y Omoto, S Shibata, RY Igarashi, K Hasegawa, T Ariyasu, M Sonoyama, T |
| author_sort | Iwata, S |
| collection | OXFORD |
| description | <p>We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3 study, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naïve participants (aged ≥ 18 years, without prior infection or vaccination against SARS-CoV-2) were randomized (1:1) to receive either S-268019-b or ChAdOx1 nCoV-19 as two intramuscular injections given 28 days apart. Participants who provided consent for a booster administration received S-268019-b at Day 211. The primary endpoint was SARS-CoV-2 neutralizing antibody (NAb) titer on Day 57; the key secondary endpoint was the seroconversion rate for SARS-CoV-2 NAb titer on Day 57. Other endpoints included anti–SARS-CoV-2 S-protein immunoglobulin (Ig)G antibody titer and safety. The demographic and baseline characteristics were generally comparable between S-268019-b (n = 611) and ChAdOx1 nCoV-19 (n = 610) groups. S-268019-b showed superior immunogenicity over ChAdOx1 nCoV-19, based on their geometric mean titers (GMTs) and GMT ratios of SARS-CoV-2 NAb on Day 57 by cytopathic effect assay (GMT [95% confidence interval {CI}] 19.92 [18.68, 21.23] versus 3.63 [3.41, 3.87]; GMT ratio [95% CI] 5.48 [5.01, 6.00], respectively; two-sided <em>p</em>-values < 0.0001). Additionally, NAb measured using a cell viability assay also showed similar results (GMT [95% CI] 183.25 [168.04, 199.84] versus 24.79 [22.77, 27.00]; GMT ratio [95% CI] 7.39 [6.55, 8.35] for S-268019-b versus ChAdOx1 nCoV-19, respectively; <em>p</em> < 0.0001). The GMT of anti–SARS-CoV-2 S-protein IgG antibody was 370.05 for S-268019-b versus 77.92 for ChAdOx1 nCoV-19 on Day 57 (GMT ratio [95% CI] 4.75 [4.34, 5.20]). Notably, immune responses were durable through the end of the study. S-268019-b elicited T-helper 1 skewed T-cell response, comparable to that of ChAdOx1 nCoV-19. After the first dose, the incidence of solicited systemic treatment-related adverse events (TRAEs) was higher in the ChAdOx1 nCoV-19 group, but after the second dose, the incidence was higher in the S-268019-b group. Headache, fatigue, and myalgia were the most commonly reported solicited systemic TRAEs, while pain at the injection site was the most frequently reported solicited local TRAE following both doses in both groups. No serious treatment-related adverse serious TRAEs events were reported in the two groups. S-268019-b was more immunogenic than ChAdOx1 nCoV-19 vaccine and was well tolerated (jRCT2051210151).</p> |
| first_indexed | 2024-09-25T04:17:33Z |
| format | Journal article |
| id | oxford-uuid:a261dd4b-3bc9-4cc2-8d5d-789d696c7262 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:17:33Z |
| publishDate | 2024 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:a261dd4b-3bc9-4cc2-8d5d-789d696c72622024-07-20T14:58:30ZA phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adultsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a261dd4b-3bc9-4cc2-8d5d-789d696c7262EnglishSymplectic ElementsSpringer Nature2024Iwata, SPollard, AJTada, YOmoto, SShibata, RYIgarashi, KHasegawa, TAriyasu, MSonoyama, T<p>We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3 study, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–naïve participants (aged ≥ 18 years, without prior infection or vaccination against SARS-CoV-2) were randomized (1:1) to receive either S-268019-b or ChAdOx1 nCoV-19 as two intramuscular injections given 28 days apart. Participants who provided consent for a booster administration received S-268019-b at Day 211. The primary endpoint was SARS-CoV-2 neutralizing antibody (NAb) titer on Day 57; the key secondary endpoint was the seroconversion rate for SARS-CoV-2 NAb titer on Day 57. Other endpoints included anti–SARS-CoV-2 S-protein immunoglobulin (Ig)G antibody titer and safety. The demographic and baseline characteristics were generally comparable between S-268019-b (n = 611) and ChAdOx1 nCoV-19 (n = 610) groups. S-268019-b showed superior immunogenicity over ChAdOx1 nCoV-19, based on their geometric mean titers (GMTs) and GMT ratios of SARS-CoV-2 NAb on Day 57 by cytopathic effect assay (GMT [95% confidence interval {CI}] 19.92 [18.68, 21.23] versus 3.63 [3.41, 3.87]; GMT ratio [95% CI] 5.48 [5.01, 6.00], respectively; two-sided <em>p</em>-values < 0.0001). Additionally, NAb measured using a cell viability assay also showed similar results (GMT [95% CI] 183.25 [168.04, 199.84] versus 24.79 [22.77, 27.00]; GMT ratio [95% CI] 7.39 [6.55, 8.35] for S-268019-b versus ChAdOx1 nCoV-19, respectively; <em>p</em> < 0.0001). The GMT of anti–SARS-CoV-2 S-protein IgG antibody was 370.05 for S-268019-b versus 77.92 for ChAdOx1 nCoV-19 on Day 57 (GMT ratio [95% CI] 4.75 [4.34, 5.20]). Notably, immune responses were durable through the end of the study. S-268019-b elicited T-helper 1 skewed T-cell response, comparable to that of ChAdOx1 nCoV-19. After the first dose, the incidence of solicited systemic treatment-related adverse events (TRAEs) was higher in the ChAdOx1 nCoV-19 group, but after the second dose, the incidence was higher in the S-268019-b group. Headache, fatigue, and myalgia were the most commonly reported solicited systemic TRAEs, while pain at the injection site was the most frequently reported solicited local TRAE following both doses in both groups. No serious treatment-related adverse serious TRAEs events were reported in the two groups. S-268019-b was more immunogenic than ChAdOx1 nCoV-19 vaccine and was well tolerated (jRCT2051210151).</p> |
| spellingShingle | Iwata, S Pollard, AJ Tada, Y Omoto, S Shibata, RY Igarashi, K Hasegawa, T Ariyasu, M Sonoyama, T A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults |
| title | A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults |
| title_full | A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults |
| title_fullStr | A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults |
| title_full_unstemmed | A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults |
| title_short | A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults |
| title_sort | phase 3 randomized controlled trial of a covid 19 recombinant vaccine s 268019 b versus chadox1 ncov 19 in japanese adults |
| work_keys_str_mv | AT iwatas aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT pollardaj aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT taday aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT omotos aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT shibatary aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT igarashik aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT hasegawat aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT ariyasum aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT sonoyamat aphase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT iwatas phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT pollardaj phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT taday phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT omotos phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT shibatary phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT igarashik phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT hasegawat phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT ariyasum phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults AT sonoyamat phase3randomizedcontrolledtrialofacovid19recombinantvaccines268019bversuschadox1ncov19injapaneseadults |